Medfinder
Back to blog

Updated: January 23, 2026

Prevymis Side Effects: What to Expect and When to Call Your Doctor

Author

Peter Daggett

Peter Daggett

Medication bottle with checklist showing checkmarks and warning symbols

Learn about Prevymis (letermovir) common and serious side effects, what symptoms require urgent care, and how Prevymis compares to other CMV drugs for tolerability.

Prevymis (letermovir) is generally well-tolerated compared to older antiviral drugs used for CMV prophylaxis. But like any medication, it can cause side effects. Understanding which side effects are common and manageable — and which require urgent medical attention — is important for anyone taking this drug after a transplant.

Common Side Effects of Prevymis

The most common side effects reported in clinical trials of Prevymis (occurring in at least 10% of patients in the Prevymis group and at least 2% more often than placebo) include:

  • Nausea — One of the most frequently reported side effects. Usually mild to moderate and often improves over time. Taking Prevymis with food may help.
  • Diarrhea — Common with oral forms. In kidney transplant patients, diarrhea was the most common side effect reported. Stay hydrated and tell your doctor if it is severe.
  • Vomiting — May occur with nausea; if you vomit your tablet, do not retake the dose — wait for your next scheduled dose.
  • Peripheral edema (swelling of the limbs) — Fluid retention in arms and legs; reported in post-transplant patients, though also common in this patient population generally due to immunosuppressants.
  • Cough — Persistent cough reported; notify your doctor so CMV pneumonitis and other pulmonary complications can be ruled out.
  • Headache — Usually mild; over-the-counter pain relief may help but check with your transplant team before taking any new medications.
  • Fatigue / tiredness — Common in post-transplant patients; may be related to the underlying illness, other medications, or Prevymis itself.
  • Abdominal pain — Stomach cramping or discomfort; report persistent or worsening abdominal pain to your doctor.

How Prevymis Side Effects Compare to Valganciclovir

One of Prevymis's key advantages over older CMV drugs is a significantly more favorable bone marrow safety profile. In a head-to-head phase 3 trial comparing letermovir to valganciclovir in kidney transplant patients:

  • Leukopenia or neutropenia (dangerously low white blood cells): 26% in Prevymis group vs. 64% in valganciclovir group
  • Discontinuation due to adverse events: 4.1% with Prevymis vs. 13.5% with valganciclovir

This means Prevymis is much less likely to suppress your immune system's blood cell production, which is a critical advantage in transplant patients who are already immunocompromised.

Serious Side Effects to Watch For

While Prevymis is generally well-tolerated, there are serious safety concerns to be aware of:

  • Drug interactions causing serious harm: Prevymis affects many enzymes (CYP3A, CYP2C8, OATP1B1/3) and can raise levels of other drugs to dangerous ranges. Symptoms of drug interactions may include irregular heartbeat, severe muscle pain, confusion, or signs of liver damage. Always report any new symptoms to your doctor and never start new medications without checking interactions.
  • Allergic reactions: Though rare, Prevymis can cause allergic reactions. Seek emergency care immediately if you experience hives, difficulty breathing, fast heartbeat, or swelling of the face, lips, tongue, or throat.
  • Hearing concerns with IV form: The IV formulation contains hydroxypropyl betadex, which animal studies show may cause ototoxicity (hearing damage), particularly in patients with kidney disease. The IV form should be used only in patients unable to take oral therapy and switched to oral Prevymis as soon as possible.

When to Call Your Doctor Immediately

Contact your transplant doctor or call emergency services right away if you experience:

  • Difficulty breathing or chest tightness
  • Severe muscle pain or weakness (possible rhabdomyolysis if on certain statins)
  • Signs of an allergic reaction (hives, swelling, fast heartbeat)
  • Severe diarrhea or vomiting preventing you from keeping the medication down
  • Yellowing of skin or eyes (jaundice) — signs of possible liver problems
  • Irregular or racing heartbeat

Tips for Managing Common Prevymis Side Effects

  • Nausea: Take Prevymis tablets with a small amount of food. Eating smaller, more frequent meals can help. Ask your doctor if a short-term anti-nausea medication is appropriate.
  • Diarrhea: Stay well hydrated. Avoid high-fiber foods and caffeine when symptoms are active. Check with your doctor before using over-the-counter anti-diarrheal medications.
  • Peripheral edema: Elevate your legs when sitting. Reduce sodium intake. Alert your transplant team if swelling worsens significantly.

For a detailed look at drug interactions that can cause serious side effects with Prevymis, see our guide: Prevymis Drug Interactions: What to Avoid.

Frequently Asked Questions

The most common side effects of Prevymis (letermovir) reported in clinical trials include nausea, diarrhea, vomiting, peripheral edema (swelling of the arms and legs), cough, headache, fatigue, and abdominal pain. These occur in at least 10% of patients and are generally mild to moderate in severity.

Prevymis (letermovir) causes significantly less bone marrow suppression than older CMV drugs like valganciclovir. In a head-to-head phase 3 trial, leukopenia or neutropenia occurred in only 26% of letermovir patients compared to 64% of valganciclovir patients. This is one of the main clinical advantages of Prevymis.

Oral Prevymis (tablets or pellets) does not require dose adjustment based on kidney function. However, the IV formulation contains hydroxypropyl betadex, which can accumulate in patients with CrCl <50 mL/min and may cause hearing problems. Patients with kidney disease should use oral Prevymis whenever possible. Serum creatinine should be monitored in patients on IV Prevymis with renal impairment.

Prevymis is not recommended in patients with severe hepatic impairment (Child-Pugh Class C), as letermovir concentrations are approximately 4 times higher in these patients. Patients with mild to moderate hepatic impairment (Child-Pugh A or B) do not require dose adjustment. Report any signs of liver problems (jaundice, dark urine, severe abdominal pain) to your doctor immediately.

Medfinder Editorial Standards

Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.

Read our editorial standards

Patients searching for Prevymis also looked for:

37,258 have already found their meds with Medfinder.

Start your search today.

37K+
5-star ratingTrusted by 37,258 Happy Patients
      What med are you looking for?
⊙  Find Your Meds
99% success rate
Fast turnaround time
Never call another pharmacy

Need this medication?